Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (NCT03600441)

🧪 Interventions in This Study

• Abexinostat (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Is able to understand and voluntarily sign an informed consent document before any study related assessments/procedures are conducted.
2. Has histologically confirmed Grade 1, 2, or 3a follicular lymphoma.
3. Has follicular lymphoma that has relapsed after (progressed after 6 months from the start of therapy) or is refractory to the last line of therapy (no response or progression within 6 months from the start of therapy) and needs treatment (must have at least 1 lymph node or extranodal lymphoid malignancy radiologically measuring ≥ 3 cm in its longest diameter).
4. Female patients must fulfil the following criteria: a. Be of non-childbearing potential, defined as follows: i. Postmenopausal (ie, ≥ 1 year without any menses) prior to Screening, or ii. Documented surgically sterile (≥ 1 month prior to Screening)
5. Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.
6. Use highly effective forms of birth control (women of childbearing potential only), which include the following: i. Consistent and correct use of established oral contraception ii. Established intrauterine device or intrauterine system iii. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
7. Female patients must agree not to breastfeed starting from the time of Screening, throughout the study, and until after 90 days following the last dose.
8. Male patients and their female spouse/partners who are of childbearing potential must use highly effective contraception methods consisting of 2 forms of birth control (at least 1 of which must be a barrier method) from the time of Screening, throughout the study, and until after 90 days following the last dose.
9. Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (15 Sites)

• Advocate Medical Group - Park Ridge, Luther Lane - Oncology — Park Ridge, Illinois
• Norton Cancer Institute - St. Matthews Campus — Louisville, Kentucky
• Clinical Research Alliance Inc — Lake Success, New York
• Manhattan Hematology Oncology Center — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Bone Marrow Transplant Hematology Oncology Associates — Pittsburgh, Pennsylvania
• Arlington Cancer Center — Arlington, Texas
• Central Texas Veterans Health Care System - NAVREF — Temple, Texas
• Vista Oncology Inc. PS — Olympia, Washington
• Centre Hospitalier de Perpignan — Perpignan, Pyrénées-Orientales
• Hospital Universitario de Donostia — Donostia / San Sebastian, Guipúzcoa
• Hospital Universitario Vall d'Hebrón — Barcelona,
• Hospital del Mar — Barcelona,
• C.H. Regional Reina Sofia — Córdoba,
• Hospital Universitario Infanta Leonor — Madrid,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
• 💵 Compensation indicated: Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.

More studies in Follicular Lymphoma

• A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas — New York, New York
• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — Bethesda, Maryland
• Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma — Basking Ridge, New Jersey
• A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma — Houston, Texas
• Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma — New Haven, Connecticut
• Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma — Fort Myers, Florida

Explore by condition: All Follicular Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.